No abstract

the TZM group. 5-year survival was 100% in TZM group vs. 90.4% in the control (p¼0.038). On multivariate analysis grade III tumor was significantly correlated with DFS (Hazard ratio [HR], 5.5, 95%CI: 0.92-9.5, p¼0.004). Lack of adjuvant TZM (HR, 3.0, 95%CI: 0.92-9.5) did not correlate with DFS.Conclusions: Overall outcomes of women with HER2+ T1a/bN0 BC is good. Women who received adjuvant TZM had numerically better DFS and a significantly better overall survival. High-grade tumor was correlated with inferior disease-free survival.Legal entity responsible for the study: Shahid Ahmed.